tbuckley/cabot-search huggingface dataset:
Laser therapy for radio-induced oral mucositis and skin dermatitis: Oral medicine, radiotherapy and oncology shared experience from the University of Trieste.
Authors: Margherita Gobbo, Alessandra Guglielmi, Giulia Ottaviani, Katia Rupel, Serena Zacchigna, Francesca Ciriello, Aulo Beorchia, Roberto Di Lenarda, Matteo Biasotto
Journal: Journal of Clinical Oncology (2015)

213 Background: Oral mucositis (OM) and dermatitis (RD) are serious side effects of radiotherapy (RT), often leading to its suspension, need for analgesics and enteral/parenteral nutrition. Laser-therapy is becoming a recommended option for mucosal lesions and has also been tested for skin affections. This prospective study investigates the effect of Laser-therapy (HPLT) on RT-induced OM and proposes an off-label use of HPLT to treat RD in breast-cancer patients and in RT-treated anal-carcinoma patients Methods: 53 cancer patients, during/after RT and/or chemotherapy, affected by OM, were treated with HPLT during 4 consecutive days (970nm, 2,5W, 35-6000Hz, 240s). Assessment of OM (WHO-SCALE: Grading objective Scale), pain (VAS: Visual Analogue Scale), functional ability, subjective parameters, site/severity of OM were recorded weekly for 21 days. 27 breast-cancer patients and 2 anal-carcinoma patients affected by RD were treated by HPLT every other day for 2 weeks (970nm/660nm, 2-1000Hz, 6W, 480s) and monitored weekly for one month for grade, discomfort, itching and bleeding. Results: Regarding OM, regressive improvement of WHO- SCALE from day 7 on, and of VAS from day 2 on (p &lt; 0.000) was registered. All patients’ functional capacity improved on day 4 (p &lt; 0.05). All subjective parameters improved on day 14 (p &lt; 0.001) except voice, which improved on day 21 (p &lt; 0.000). Ulcerations’ dimension and erythema’s severity decreased in all sites (p &lt; 0.05). Regarding breast and anal RD, after 6 HPLT’s sessions, complete and progressive resolution of pain, bleeding and itching was registered (p &lt; 0.002). All patients referred maximum satisfaction for receiving HPLT. Conclusions: Regardless of OM grade/site and of kind/site of tumor, HPLT was effective in healing OM. Moreover, HPLT resulted an innovative and highly effective therapy for RD, both in breast and anal lesions. To establish an effective treatment strategy for OM and RD is of paramount importance to improve life-quality of patients but can also be beneficial for the continuation of cancer therapy. Consequently, HPLT may become integral part of everyday-practice in the management of RT adverse effects.
The Use of Angioplasty, Bypass Surgery, and Amputation in the Management of Peripheral Vascular Disease
Authors: Sean R. Tunis, Eric B. Bass, Earl P. Steinberg
Journal: New England Journal of Medicine (1991)

Percutaneous transluminal angioplasty has been adopted widely as a treatment for patients with peripheral vascular disease of the lower extremities. However, the effect of this procedure on the overall management of peripheral vascular disease and on the outcomes of patients has not been clearly delineated. In particular, it is not known whether angioplasty has replaced other treatments for peripheral vascular disease.
786 HEPATITIS C TRIPLE THERAPY INDUCED ANEMIA. IS TREATMENT WITH ERYTHROPOIETIN JUSTIFIED?
Authors: T. Álvarez-Malé, R. López-Rodríguez, M.J. Borque, Y. Rodríguez- Muñoz, Á. Herna'ndez-Bartolomé, L. González-Moreno, Y. Real, R. Moreno-Otero, P. Sanz-Cameno, L. García-Buey
Journal: Journal of Hepatology (2013)
EUS-FNI of AdV-TK Gene Transfer Therapy in Combination with Chemoradiation Therapy for Locally Advanced Pancreatic Cancer: A Case Report
Authors: J Lin
Journal: Endoscopy (2011)

Adenovirus-mediated delivery of the herpes simplex virus thymidine kinase (AdV-TK) into tumor cells with the administration of an antiherpetic prodrug has shown in vitro and in vivo efficacy in different animal models, and has been applied to various malignancies (prostate, brain, ovarian, hepatocellular) in Phase I/II trials. After injection of the AdV-TK into tumor cells, the thymidine kinase is replicated and converts prodrug (valacyclovir) into toxic nucleotide analogues which are incorporated into DNA during cell division, terminating cell division and leading to cell death. A potential secondary benefit is the ‘by-stander’ effect by which the AdV-TK may induce the induction of the host antitumor immune response.
CULPRIT LESIONS OF ACUTE CORONARY SYNDROME ARE CHARACTERIZED BY THE PRESENCE OF STENOSIS AND HIGH-RISK PLAQUE, BUT NOT HIGHER SEGMENTAL CORONARY ARTERY CALCIUM SCORE: RESULTS FROM THE ROMICAT II TRIAL
Authors: Maros Ferencik, Stefan B. Puchner, Thomas Mayrhofer, Michael T. Lu, Ting Liu, Pal Maurovich-Horvat, Khristine Ghemigian, Jerome Fleg, James Udelson, Udo Hoffmann
Journal: Journal of the American College of Cardiology (2015)
Arterial Abnormalities in the Offspring of Patients with Premature Myocardial Infarction
Authors: Giovanni Gaeta, Mario De Michele, Sergio Cuomo, Pasquale Guarini, Maria C. Foglia, M. Gene Bond, Maurizio Trevisan
Journal: New England Journal of Medicine (2000)

The offspring of patients with premature coronary disease may be at increased risk for atherosclerosis. We undertook a study to determine whether changes in brachial-artery reactivity and the thickness of the carotid intima and media, two markers of early atherosclerosis, are present in adolescents and young adults with a parental history of premature myocardial infarction.
Abstract 1520: Estrogen modulates angiogenic factors of thyroid tumor microenvironment
Authors: Shilpi Rajoria, Andrea George, Robert Suriano, Edward J. Shin, Jan Geliebter, Raj K. Tiwari
Journal: Cancer Research (2012)

Abstract Thyroid cancer is the most common endocrine related cancer with the incidences occurring three to four times higher in women than in men, thus suggesting that estrogen plays a critical role in thyroid cancer progression. We have previously demonstrated that thyroid cancer cells express functionally active estrogen receptors (ER), ER-α and ER-α and that estrogen enhances the metastatic propensity of thyroid cancer cells by increased migration, adhesion and invasion, potentially mediated by enhanced secretion of matrix metalloproteinases (MMP), MMP-2 and MMP-9. However, to successfully grow and metastasize, thyroid cancer cells must initiate endothelial cell induced neo-vascularization such that adequate blood supply is maintained within the tumor. In an effort to define the interacting factors between endothelial cells and thyroid cancer epithelial cells, we developed an in vitro cell culture based system using three thyroid cancer cell lines (a papillary thyroid carcinoma cell line B-CPAP, and two follicular thyroid carcinoma cell lines, CGTH-W-1 and ML-1) and human umbilical vein endothelial cell (HUVECs). We observed that conditioned medium from estrogen treated thyroid cancer cells induced prolific tubulogenesis of endothelial cells which was abrogated in presence of the anti-estrogen, fulvestrant or neutralizing antibody to vascular endothelial growth factor (VEGF). We also observed that conditioned medium from thyroid cancer cells was able to induce migration of endothelial cells, again a phenomenon which was abrogated by fulvestrant and VEGF neutralizing antibodies. We further demonstrate that estrogen acts as a modulator of endothelial-epithelial cell interaction by modulating angiogenic factors that include VEGF and MMPs, which in turn induce mitogenic signaling and help promote and maintain cellular tumor heterogeneity. Estrogen modulated tumor modulating factors are viewed as novel therapeutic targets and provide evidence that the higher incidence of thyroid cancer in females is potentially attributed to the presence of a functional ER that mediates upregulation of pro-angiogenic factors and thus anti-estrogens can be potentially used to treat and/or prevent thyroid cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1520. doi:1538-7445.AM2012-1520
THU0110 The Expression and Significance of NALP1 and IPAF in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
Authors: Y. Pan, Z. Song, L. Fang, X. Guo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It is known that IL-1 has played an important role in the progression of rheumatoid arthritis. IPAF [the IL1B converting enzyme (ICE)-protease activating factor] and NALP [NOD and the NTPases implicated in apoptosis and multihistocompatability complex transcription (NACHT) leucine-rich repeat protein] 1 are important components of inflammasome, which can promote the synthesis of certain cytokines such as IL-1beta. We supposed that IPAF and NALP1 might have some relationship with RA inflammation, because of their role in inflammatory reaction. <h3>Objectives</h3> To investigate the expression of IPAF and NALP1, and study the influence of TNF-α, LPS and Z-VAD-FMK on NALP1 and IPAF in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). <h3>Methods</h3> All of the synovial tissues were obtained during joint replacement surgery and arthroscopic operation from 6 patients with RA, 4 with OA and 3 with joint trauma. The NALP1 and IPAF protein expression was tested by immunohistochemical in synovial tissue. FLS were cultured in vitro. The mRNA and protein expression of NALP1 and IPAF was detected by Real-time PCR and western blotting respectively. RA-FLS were treated with LPS, LPS+Z-VAD-FMK, TNF-α and TNF-α+Z-VAD-FMK. Then the mRNA and protein expression of NALP1 and IPAF was tested by Real-time PCR and western blotting. <h3>Results</h3> Immunohistochemistry revealed that the expression of IPAF in synovial lining cells of RA samples was significantly higher than that of OA or Trauma (p&lt;0.05). NALP1 was expressed in RA samples only, but not expressed in OA and Trauma samples (P&lt;0.05). Western blotting and Real-time PCR showed that IPAF expression in OA-FLS &gt; that in RA-FLS &gt; that in Trauma-FLS (p&lt;0.05). NALP1 expression at the mRNA level in OA-FLS was greater than that in RA-FLS, which is more than that in Trauma-FLS (p&lt;0.05). But no difference of NALP1 expression was found at the protein level in the three groups above. The mRNA and protein expression of IPAF in RA-FLS which was treated with TNF-α was 4.08 times more than that in control (both p&lt;0.05), and was also more than that treated with TNF-α+ Z-VAD-FMK (both p&lt;0.05). The mRNA expression of NALP1 in the RA-FLS treated with TNF-α was 1.19 times of that in control. But there was no difference between the NALP1 expression in RA-FLS treated with different drugs (p&gt;0.05). <h3>Conclusions</h3> Theses results suggest that IPAF and NALP1 may be involved in RA chronic synovial inflammation process. TNF-α can promote the expression of IPAF in RA-FLS, and this effect can be inhibited by Z-VAD-FMK—the inhibitor of caspase which is located in the downstream of inflammasome, reconfirming the effect dependents on inflammatory. <h3>References</h3> Sidiropoulos PI, Goulielmos G, Voloudaskis GK, et al. Inflammasomes and rheumatic diseases: evolving concept [J]. Ann Rheum Dis, 2008,67(10):1382-1389. <h3>Disclosure of Interest</h3> None Declared
P728 HEPATITIS C VIRUS (HCV) CORE ANTIGEN ASSAY FOR DETECTION OF ACTIVE HCV INFECTION AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN ATTENDING AN STI CLINIC
Authors: J.W. Vanhommerig, T.J.W. van de Laar, M.S. van Rooijen, H.J. de Vries, A.G.C.L. Speksnijder, M. Prins, S.M. Bruisten
Journal: Journal of Hepatology (2014)
O4.02 * EXOSOMAL MIRNA FROM GLIOMA-ASSOCIATED MESENCHYMAL STEM CELLS PROMOTE GLIOMA GROWTH AND PROGRESSION
Authors: J. M. Figueroa, T. Shahar, A. Hossain, J. Gumin, F. Lang
Journal: Neuro-Oncology (2014)

Evidence indicates that human cancers are maintained by a population of cells with stem-like properties called cancer stem cells (CSCs). However, the influence of the surrounding stromal cells on the behavior of the CSCs remains poorly understood. We have recently shown that the micro-environment of human gliomas, the most aggressive human brain tumors, contains both glioma stem cells (GSCs) and cells that resemble human bone marrow-derived mesenchymal stem cells (BM-MSCs), called Glioma Associated-MSCs (GA-MSCs). We have also shown that GA-MSCs generate a cytokine-mediated increase in the growth and self-renewal (clonogenicity) of GSCs. However, other paracrine interactions between GA-MSCs and GSCs have not been fully explored. Recent studies have suggested that nano-sized vesicles, termed exosomes, may contribute to intercellular communication within the tumor niche. Therefore, we hypothesized that GA-MSC-derived exosomes increase the tumorigenicity GSCs. Here we show for the first time that exosomes can be isolated from patient-derived GA-MSCs and that these exosomes contain oncogenic microRNAs. Importantly, in vitro delivery of exosomes isolated from GA-MSCs significantly increased both the proliferation and clonogenicity of GSCs. Furthermore, GSC xenografts, treated with GA-MSC-derived exosomes, in the brains of nude mice resulted in a greater tumor burden and significantly decreased animal survival. Delivery of microRNA from GA-MSC-derived exosomes to GSCs, was enough to alter the gene expression profile resulting in the glioma-enhancing effects described. We conclude that GA-MSC-derived exosomes represent an alternative intercellular communication mechanism for the transfer of specific microRNA, which enhances the aggressive nature of Glioblastoma.
PTH-062 Endoscopic Mucosal Resection of Large Colorectal Polyps in Non Screening Colonoscopies Has a High Recurrence Rate:: Abstract PTH-062 Table 1
Authors: S M Ali, R Kalla, M Hendrickse
Journal: Gut (2013)

<h3>Introduction</h3> EMR of large colorectal polyps has been reported to be a safe and effective technique in UK. Although the success of large polyp EMR has been reported within regional bowel cancer screening centres, there is a paucity of data comparing outcomes between screening and non-screening centres. <h3>Methods</h3> A total of 61 screening and 60 non-screening EMR of polyps 2cm or greater were performed from January 2008 to December 2011. Data was collected from 3 hospitals for screening EMR and 1 district hospital for non-screening EMR. <h3>Results</h3> The table below summarises the findings at initial EMR for both groups. Surveillance data was available for 37 patients in the non-screening group compared to all 61 patients in the screening group up-to 3 months post EMR. Number of recurrences were 6 (10%) with mean polyp size of 25mm in the screening group compared to 10 (27%) in the non screening group with mean polyp size of 50mm. All recurrences in both groups were resected and complete. Histology confirmed low grade dysplasia (LGD) in 80%, while 2 patients had evidence of high grade dysplasia (HGD) in the non-screening group. All showed LGD in the screening group. At 12 months surveillance post EMR, 43 screening patients had follow-up data with 8 recurrences detected compared to 14 in the non screening group with 4 recurrences. <h3>Conclusion</h3> Endoscopic mucosal resection of polyps in screening group appears to be safer with low complication rates and low recurrence rate up to 12 months post EMR compared to the non-screening groups. This may be due to a multitude of factors such as patient age, co-morbidites and the characteristics of polyps. Clinical features of patients undergoing EMR were similar in both groups. There was a trend to higher recurrence and complication rate in the non screening group. The follow up post EMR was less consistent in the non screening group possibly due to less stringent protocols for follow up. This may have affected the surveillance and recurrence rates. <h3>Disclosure of Interest</h3> None Declared. <h3>References</h3> Lim TR, Mahesh V, Singh S,<i> et al.</i> Endoscopic mucosal resection of colorectal polyps in typical UK hospitals.<i> World J Gastroenterol</i>.2010; 16(42): 5324–8. Boix J, Lorenzo-Zúñiga V, Moreno de Vega V, <i>et al.</i> Endoscopic removal of large sessile colorectal adenomas: is it safe and effective? <i>Dig Dis Sci</i> 2007; <b>52</b>: 840–844 Salama M, Ormonde D, Quach T, <i>et al.</i> Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience. <i>J Gastroenterol Hepatol</i><i></i> 2010; <b>25</b>: 84–89
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Authors: Curt R. Freed, Paul E. Greene, Robert E. Breeze, Wei-Yann Tsai, William DuMouchel, Richard Kao, Sandra Dillon, Howard Winfield, Sharon Culver, John Q. Trojanowski, David Eidelberg, Stanley Fahn
Journal: New England Journal of Medicine (2001)

Transplantation of human embryonic dopamine neurons into the brains of patients with Parkinson's disease has proved beneficial in open clinical trials. However, whether this intervention would be more effective than sham surgery in a controlled trial is not known.
Abstract 5146: Phosphositeplus® and protein modifications in cancer, a case study: profiling tyrosine phosphorylated sites in AML and CML.
Authors: Peter Hornbeck, Bin Zhang, Beth Murray, Elzbieta Skrzypek, Jon Kornhauser, Vaughan Latham
Journal: Cancer Research (2013)

Abstract PhosphoSitePlus® (PSP) is an open, comprehensive, manually curated, and interactive resource for studying experimentally observed post-translational modifications, primarily of human and mouse proteins. It encompasses over 250,000 non-redundant modification sites, primarily phosphorylation, ubiquitinylation and acetylation. The results of thousands of mass spec experiments, many from various cancers, are aggregated and available for downloading from PSP. The cancers that are most widely represented in PSP include non-small cell lung cancer (NSCLC), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), breast cancer (BRC), and gastric (GAC) cancer. In order to determine if the sort of binary data in PSP can be useful in identifying sites that are differentially tyrosine phosphorylated between various cancers, 284 CML and 160 AML datasets were downloaded from PSP and analyzed. Differences in the expression of tyrosine phosphorylation were observed: sites that were elevated in AML included PAG1 Tyr317/359/417, WASP Tyr291, SHP-1 Tyr536, and E-Syt1 Tyr822. Sites that were elevated in CML included Bcr and Abl sites as expected, as well as DYRK1A Tyr145, VASP Tyr39, CD2AP Tyr88, SHIP-2 Tyr986/1135/1162. These meta-analyses demonstrate that PSP provides a rich source of easily accessible data that enables proteomic profiling of multiple cancers. See www.phosposite.org Supported by NIH R44 CA126080, R43 GM65768, and R44 AA014848 Citation Format: Peter Hornbeck, Bin Zhang, Beth Murray, Elzbieta Skrzypek, Jon Kornhauser, Vaughan Latham. Phosphositeplus® and protein modifications in cancer, a case study: profiling tyrosine phosphorylated sites in AML and CML. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5146. doi:10.1158/1538-7445.AM2013-5146
Case 18-1995
Authors: A.F. Fuller, D.C. Fleischhacker
Journal: New England Journal of Medicine (1995)

Presentation of CaseA 59-year-old woman was admitted to the hospital because of increasing constipation, abdominal pain, and a rectosigmoid mass.The patient had been well until three months earlier, when pain in the right lower quadrant and constipation developed and gradually worsened; she passed mucus in her stools, without blood. Three weeks before admission colonoscopic examination at the gastrointestinal clinic showed a concentric mass, approximately 8 cm in diameter, in the sigmoid colon, with nearly complete obstruction. A pediatric endoscope was passed into the ascending colon with difficulty. No further abnormalities were observed. It was noted that the mucosa . . .
Abstract 3016: Implication of delta-catenin-promoted E-cadherin processing on human prostate cancer progression.
Authors: Hangun Kim, Somy Yoon, So-Yeon Park, Jun Eul Hwang, Kwonseop Kim, Kyung Keun Kim
Journal: Cancer Research (2013)

Abstract Although δ-catenin overexpression is frequently observed in some human cancers, the mechanistic implications of δ-catenin expression in epithelial cells and carcinomas remain elusive. In this study, we found that prostate cancer cells overexpressing δ-catenin show an increase in multi-layer growth in culture. In these cells, δ-catenin colocalizes with E-cadherin at the plasma membrane, and the E-cadherin processing is noticeably elevated. A deletion mutant of δ-catenin totally abolishes the δ-catenin-induced E-cadherin processing and the multi-layer growth of the cells. In addition, prostate cancer cells overexpressing δ-catenin display an elevated total β-catenin level and increase nuclear distribution, resulting in the activation of β-catenin/LEF-1-mediated transcription. Indeed, human prostate tumor xenograft in nude mice, which is derived from cells overexpressing δ-catenin, shows increased β-catenin nuclear localization and more rapid growth rates. Moreover, the metastatic xenograft tumor weights positively correlate with the level of 29 kD E-cadherin fragment, and primary human prostate tumor tissues also show elevated levels of δ-catenin expression and the E-cadherin processing. Taken together, these results suggest that δ-catenin plays an important role in prostate cancer progression through inducing E-cadherin processing and thereby activating β-catenin-mediated oncogenic signals. Citation Format: Hangun Kim, Somy Yoon, So-Yeon Park, Jun Eul Hwang, Kwonseop Kim, Kyung Keun Kim. Implication of delta-catenin-promoted E-cadherin processing on human prostate cancer progression. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3016. doi:10.1158/1538-7445.AM2013-3016 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.